Stem cell transplant help for children lacking a matching sibling
Part of Blood & lymphatic, Cancer, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This expanded-access study offers a specific type of stem cell transplant preparation that removes certain immune cells (CD3 and CD19) from donor stem cells. It is for children who need a transplant but do not have a fully matched sibling donor and whose team cannot use the hospital’s usual matching device protocol.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need a stem cell transplant for a serious blood, immune, or metabolic condition your team recommends
- You do NOT have a fully HLA-matched sibling donor (a close genetic match)
- Your child’s care team says the usual CD3/CD19 depletion method at this hospital is not suitable for you
- A living donor is available who can donate stem cells (related or matched unrelated donor)
- Your child can join the transplant plan safely: generally good strength/activity (Lansky/Karnofsky 60+), and organ and infection checks meet study/hospital rules
- If you (or your child) could get pregnant, a pregnancy test must be negative
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers a special type of stem cell transplant for children and young adults. It uses a machine to remove certain immune cells (alpha/beta T cells and CD19+ cells) from the donated stem cells, which may lower the risk of graft-versus-host disease. The study includes patients who need a first transplant, a second transplant, or a stem cell boost.
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
This trial tests a type of stem cell transplant that removes certain immune cells (alpha-beta T cells and CD19 B cells) from the donor cells. This may help prevent graft-versus-host disease and other complications in patients with blood cancers who do not have a matched sibling donor.
This study tests a special stem cell transplant for children and young adults with certain high-risk blood cancers or bone marrow diseases. It uses a half-matched family donor and a technique to remove specific cells, which may lower the risk of side effects and help the body accept the new cells.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.